FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022301394> ?p ?o ?g. }

• W2022301394 endingPage "255.e3" @default.
• W2022301394 startingPage "247" @default.
• W2022301394 abstract "ObjectiveTo identify resistin in human ovarian follicles and investigate the effect and the molecular mechanisms associated with resistin on steroidogenesis in human granulosa cells (GCs).DesignThe effects of recombinant human resistin on the secretion of progesterone (P) and estradiol (E2) by cultured human GCs were investigated.SettingAcademic institutions.Patient(s)Twenty infertile and healthy women undergoing IVF.Intervention(s)Primary human GC cultures stimulated with recombinant human resistin (10 ng/mL).Main Outcome Measure(s)Determination of messenger RNA (mRNA) and protein expression of resistin in fresh human GCs by reverse transcriptase-polymerase chain reaction (RT-PCR), immunoblot and immunohistochemistry, respectively; measurement of P and E2 levels in the conditioned media by radioimmunoassay; determination of cell proliferation by tritiated thymidine incorporation; and analysis of signaling pathways activation by immunoblot analysis.Result(s)Human GCs and theca cells express resistin. In primary human GCs, resistin decreases P and E2 secretion in response to insulin-like growth factor I (IGF-I). This was associated with a reduction in the P450 aromatase and P450scc (cholesterol side-chain cleavage cytochromes P450) (P450scc) protein levels but not those of 3β-hydroxysteroid dehydrogenase (3β-HSD) or steroidogenic acute regulatory protein (StAR) and with a decrease in IGF-I-induced IGF-I receptor and mitogen-activated protein kinase (MAPK) extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation. Resistin treatment does not affect IGF-I-induced cell proliferation and basal steroidogenesis (there is no IGF-I or follicle-stimulating hormone stimulation). In the basal state, resistin rapidly stimulates Akt and MAPK ERK1/2 and p38 phosphorylation in primary human GCs.Conclusion(s)Resistin is present in human GCs and theca cells. It decreases P and E2 secretion, P450scc and P450 aromatase protein levels, and IGF-IR signaling in response to IGF-I in primary human GCs. To identify resistin in human ovarian follicles and investigate the effect and the molecular mechanisms associated with resistin on steroidogenesis in human granulosa cells (GCs). The effects of recombinant human resistin on the secretion of progesterone (P) and estradiol (E2) by cultured human GCs were investigated. Academic institutions. Twenty infertile and healthy women undergoing IVF. Primary human GC cultures stimulated with recombinant human resistin (10 ng/mL). Determination of messenger RNA (mRNA) and protein expression of resistin in fresh human GCs by reverse transcriptase-polymerase chain reaction (RT-PCR), immunoblot and immunohistochemistry, respectively; measurement of P and E2 levels in the conditioned media by radioimmunoassay; determination of cell proliferation by tritiated thymidine incorporation; and analysis of signaling pathways activation by immunoblot analysis. Human GCs and theca cells express resistin. In primary human GCs, resistin decreases P and E2 secretion in response to insulin-like growth factor I (IGF-I). This was associated with a reduction in the P450 aromatase and P450scc (cholesterol side-chain cleavage cytochromes P450) (P450scc) protein levels but not those of 3β-hydroxysteroid dehydrogenase (3β-HSD) or steroidogenic acute regulatory protein (StAR) and with a decrease in IGF-I-induced IGF-I receptor and mitogen-activated protein kinase (MAPK) extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation. Resistin treatment does not affect IGF-I-induced cell proliferation and basal steroidogenesis (there is no IGF-I or follicle-stimulating hormone stimulation). In the basal state, resistin rapidly stimulates Akt and MAPK ERK1/2 and p38 phosphorylation in primary human GCs. Resistin is present in human GCs and theca cells. It decreases P and E2 secretion, P450scc and P450 aromatase protein levels, and IGF-IR signaling in response to IGF-I in primary human GCs." @default.
• W2022301394 created "2016-06-24" @default.
• W2022301394 creator A5022649447 @default.
• W2022301394 creator A5050383346 @default.
• W2022301394 creator A5055789689 @default.
• W2022301394 creator A5062429127 @default.
• W2022301394 creator A5080683449 @default.
• W2022301394 creator A5091539631 @default.
• W2022301394 date "2013-07-01" @default.
• W2022301394 modified "2023-10-17" @default.
• W2022301394 title "Resistin decreases insulin-like growth factor I–induced steroid production and insulin-like growth factor I receptor signaling in human granulosa cells" @default.
• W2022301394 cites W1675830194 @default.
• W2022301394 cites W1968200399 @default.
• W2022301394 cites W1983325944 @default.
• W2022301394 cites W1986441106 @default.
• W2022301394 cites W1992027969 @default.
• W2022301394 cites W1994015582 @default.
• W2022301394 cites W2017363120 @default.
• W2022301394 cites W2018946767 @default.
• W2022301394 cites W2023093201 @default.
• W2022301394 cites W2023113576 @default.
• W2022301394 cites W2033250691 @default.
• W2022301394 cites W2034622046 @default.
• W2022301394 cites W2046277604 @default.
• W2022301394 cites W2049804506 @default.
• W2022301394 cites W2057477574 @default.
• W2022301394 cites W2059389550 @default.
• W2022301394 cites W2061026736 @default.
• W2022301394 cites W2066086411 @default.
• W2022301394 cites W2066576538 @default.
• W2022301394 cites W2067637912 @default.
• W2022301394 cites W2070164366 @default.
• W2022301394 cites W2083266355 @default.
• W2022301394 cites W2088085350 @default.
• W2022301394 cites W2101328621 @default.
• W2022301394 cites W2107298656 @default.
• W2022301394 cites W2110678596 @default.
• W2022301394 cites W2112152674 @default.
• W2022301394 cites W2113704542 @default.
• W2022301394 cites W2116167642 @default.
• W2022301394 cites W2120479629 @default.
• W2022301394 cites W2137831097 @default.
• W2022301394 cites W2144665600 @default.
• W2022301394 cites W2147912605 @default.
• W2022301394 cites W2149613768 @default.
• W2022301394 cites W2158360711 @default.
• W2022301394 cites W2161324995 @default.
• W2022301394 cites W2181068111 @default.
• W2022301394 cites W2324024668 @default.
• W2022301394 doi "https://doi.org/10.1016/j.fertnstert.2013.03.008" @default.
• W2022301394 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23548939" @default.
• W2022301394 hasPublicationYear "2013" @default.
• W2022301394 type Work @default.
• W2022301394 sameAs 2022301394 @default.
• W2022301394 citedByCount "27" @default.
• W2022301394 countsByYear W20223013942014 @default.
• W2022301394 countsByYear W20223013942015 @default.
• W2022301394 countsByYear W20223013942016 @default.
• W2022301394 countsByYear W20223013942017 @default.
• W2022301394 countsByYear W20223013942019 @default.
• W2022301394 countsByYear W20223013942020 @default.
• W2022301394 countsByYear W20223013942021 @default.
• W2022301394 countsByYear W20223013942022 @default.
• W2022301394 countsByYear W20223013942023 @default.
• W2022301394 crossrefType "journal-article" @default.
• W2022301394 hasAuthorship W2022301394A5022649447 @default.
• W2022301394 hasAuthorship W2022301394A5050383346 @default.
• W2022301394 hasAuthorship W2022301394A5055789689 @default.
• W2022301394 hasAuthorship W2022301394A5062429127 @default.
• W2022301394 hasAuthorship W2022301394A5080683449 @default.
• W2022301394 hasAuthorship W2022301394A5091539631 @default.
• W2022301394 hasBestOaLocation W20223013941 @default.
• W2022301394 hasConcept C104317684 @default.
• W2022301394 hasConcept C105580179 @default.
• W2022301394 hasConcept C126322002 @default.
• W2022301394 hasConcept C134018914 @default.
• W2022301394 hasConcept C170493617 @default.
• W2022301394 hasConcept C2775960820 @default.
• W2022301394 hasConcept C2776782570 @default.
• W2022301394 hasConcept C2777391703 @default.
• W2022301394 hasConcept C2778324911 @default.
• W2022301394 hasConcept C2779306644 @default.
• W2022301394 hasConcept C2779670467 @default.
• W2022301394 hasConcept C2779760629 @default.
• W2022301394 hasConcept C2780536345 @default.
• W2022301394 hasConcept C2780689927 @default.
• W2022301394 hasConcept C526171541 @default.
• W2022301394 hasConcept C55493867 @default.
• W2022301394 hasConcept C57074206 @default.
• W2022301394 hasConcept C62231903 @default.
• W2022301394 hasConcept C62478195 @default.
• W2022301394 hasConcept C71924100 @default.
• W2022301394 hasConcept C80446465 @default.
• W2022301394 hasConcept C86803240 @default.
• W2022301394 hasConcept C95444343 @default.
• W2022301394 hasConceptScore W2022301394C104317684 @default.
• W2022301394 hasConceptScore W2022301394C105580179 @default.
• W2022301394 hasConceptScore W2022301394C126322002 @default.

• next